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Rituximab in three children with relapsed/refractory B-cell acute
lymphoblastic leukaemia/Burkitt non-Hodgkin’s lymphoma
Rituximab (Rituxan or Mabthera) is a genetically engin-
eered chimaerical murine/human anti-CD20 monoclonal
antibody. This B-cell marker is expressed in all cases of mature
B-cell acute lymphoblastic leukaemia (B-ALL) and Burkitt-
lymphoma, a high-grade B-cell non-Hodgkin’s lymphoma
(B-NHL) (Maloney et al, 1997; Patte et al, 2001).
Very few data are available regarding the treatment of
children with B-ALL/NHL with rituximab (Corbacioglu et al,
2003), although the drug has been used for children with other
indications, such as post-transplant lymphoproliferative dis-
ease and B-cell mediated autoimmune diseases, e.g. autoim-
mune haemolytic anaemia (Faye et al, 2001; Zecca et al, 2003).
We here report our experiences in three children with
relapsed/refractory B-ALL/NHL who were treated with ritux-
imab on compassionate use basis.
Patient 1 was a 4-year-old boy with B-NHL with bone marrow
and central nervous system (CNS) involvement. Lymphadeno-
pathy was found in mediastinal lymph nodes, liver, spleen,
pancreas, as well as kidneys. He was treated according to the
Lymphome Malins de Burkitt (LMB)-96 group C protocol. He
recovered from two CNS relapses at 5 and 9 months after
diagnosis, but 12 months after initial diagnosis, he developed a
third relapse consisting of a tumour on the thoracic wall with a
pleural effusion. A fine-needle aspirate showed B-NHL with
CD20 positivity in >90% of the blasts. He was treated with
rituximab 375 mg/m2, and after the first infusion the thoracic
wall tumour vanished. Three more infusions of rituximab
(375 mg/m2, once weekly) were given, after which a complete
remission (CR) was established. No side effects of rituximab
have occurred. After human leucocyte antigen (HLA)-identical
bone marrow transplantation, he remained in CR for almost
5 years but died of progressive respiratory failure due to chronic
graft versus host disease of the lungs.
Patient 2 was a 3-year-old boy diagnosed with B-ALL with
CNS involvement. Two months after completing treatment
according to the LMB-96 group C protocol, he developed a
rapidly growing isolated testicular relapse. A biopsy showed that
more than 95% of tumour cells were CD20 positive. He was
treated with four infusions of rituximab 375 mg/m2, which
resulted in stable disease. Rituximab was well tolerated and no
major side effects were observed in this patient. After additional
chemotherapy the involved testis was surgically removed and
autologous stem cell transplantation (SCT) was performed.
Pathological examination of the removed testis showed no viable
tumour cells. To date, he has been in CR for 4 years.
Patient 3 was a 9-year-old girl with B-NHL, showing bone
marrow involvement and with localization of tumour in liver,
spleen, both kidneys and synovia of right knee. The blasts
were >90% CD20 positive. She was treated according to the
LMB-96 protocol. She did not achieve CR, and developed
CNS disease during treatment, as well as chemotherapy-
resistant disease in the abdominal lymph nodes and liver.
Re-induction was attempted with rituximab and repeated
intrathecal triple therapy. After eight weekly infusions of
rituximab (375 mg/m2 once a week), CR was achieved. She
was transplanted with an HLA-identical sibling donor.
Unfortunately, shortly after SCT, a CNS relapse was diag-
nosed, without evidence of other localizations, after which
she received palliative care and died from progressive CNS
leukaemia. Rituximab does penetrate into the cerebrospinal
fluid, be it at low levels of approximately 0Æ1% of serum
levels, which may explain the occurrence of a subsequent
CNS relapse without evidence for systemic disease that was
seen in this patient (Rubenstein et al, 2003).
In conclusion, rituximab seems able to induce responses in
children with relapsed/refractory mature B-ALL/NHL. Ritux-
imab is generally well tolerated, apart from a 10% risk of
infusion-related symptoms (Maloney et al, 1997). Further
studies in children are needed to clearly establish the clinical
efficacy and safety of rituximab in paediatric B-ALL/NHL and
to investigate its role in combination chemotherapy.
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protocol: highly effective multiagent chemotherapy tailored to the
tumor burden and initial response in 561 unselected children with
B-cell lymphomas and L3 leukemia. Blood, 97, 3370–3379.
Rubenstein, J.L., Combs, D., Rosenberg, J., Levy, A., McDermott, M.,
Damon, L., Ignoffo, R., Aldape, K., Shen, A., Lee, D., Grillo-Lopez,
A. & Shuman, M.A. (2003) Rituximab therapy for CNS lymphomas:
targeting the leptomeningeal compartment. Blood, 101, 466–468.
Zecca, M., Nobili, B., Ramenghi, U., Perrotta, S., Amendola, G., Rosito,
P., Jankovic, M., Pierani, P., De Stefano, P., Regazzi, B.M. &
Locatelli, F.W. (2003) Rituximab for the treatment of refractory
autoimmune hemolytic anemia in children. Blood, 101, 3857–3861.
Keywords: rituximab, B-cell acute lymphoblastic leukaemia,
B-cell non-Hodgkin’s lymphoma, children.
doi:10.1111/j.1365-2141.2004.04925.x
Endothelial cell activation and apoptosis in the thrombotic
microangiopathies
We read with interest the recent report (Jimenez et al, 2003)
that exposure of renal and cerebral microvascular endothelial
cells (MVEC) to plasmas of patients with thrombotic
thrombocytopenic purpura (TTP) leads to endothelial cell
(EC) activation but not apoptosis. This distinction was based
solely on changes in the ratio of CD62 to CD31 on released
endothelial microparticles, but it supports earlier studies from
these investigators utilizing terminal deoxynucleotidyl trans-
ferase-mediated dUTP nick end labelling (TUNEL) (Jimenez
et al, 2001). These findings are in contradistinction to the work
of our group, demonstrating MVEC activation and apoptosis,
as well as development of a procoagulant phenotype, following
TTP plasma exposure in vitro (reviewed in Laurence & Mitra,
1997).
The authors have suggested that this difference may be due
to divergent culture conditions, with our group pre-incubating
cells in medium containing fetal bovine serum but devoid of
human plasma or exogenous endothelial growth factors
(Jimenez et al, 2001). This may indeed be the case, as we have
noted that addition of normal plasma to such cultures blocks
the apoptotic effect of TTP plasma, just as normal plasma
infusions are therapeutic in most instances of clinical TTP
(Laurence & Mitra, 1997). However, Jimenez and associates
utilized an extracellular matrix (ECM) ‘attachment factor’
(Cell Systems, Kirkland, WA, USA), which may itself have
anti-apoptotic properties for certain stimuli, given the close
link between ECM composition and MVEC apoptosis in vitro
and in vivo (Mauro et al, 2004).
Yet, a disagreement over the most appropriate conditions to
unveil or amplify an apoptotic and/or activation-inducing
effect with TTP plasma – after all, cell culture itself perturbs EC
from a quiescent in vivo state to an activated phenotype (Cines
et al, 1998) – should not obfuscate the fact that EC apoptosis
has been demonstrated in involved tissues of TTP patients
utilizing TUNEL assays and morphology, together with
detection of EC circulating in the periphery, presumably
representing apoptotic or otherwise injured EC detached from
the underlying ECM (reviewed in Dang et al, 1999). Our
in vitro assays also reproduce the EC tissue lineage distinction
found in vivo in TTP, including lack of pathology in
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